Immunotherapy News and Research

Latest Immunotherapy News and Research

New molecular analysis tool to detect targets for immunotherapy in early-stage breast cancers

Yale Cancer Center researchers used a new molecular analysis tool to accurately detect the level of an important target for immunotherapy in early-stage breast cancers.

21 Jul 2014

Researchers find viable immunotherapy option for HIV-1 using fossil virus

The road to finding a cure for HIV-1 is not without obstacles. However, thanks to cutting-edge research by Douglas Nixon, M.D., Ph.D., and colleagues, performed at the George Washington University (GW), Oregon Health & Science University, the University of Rochester, and UC San Francisco, the scientific community is one step closer to finding a viable immunotherapy option for HIV-1, using an immune attack against a fossil virus buried in the genome.

18 Jul 2014

First publication describing use of CytoSorb during cardiac surgery

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany.

17 Jul 2014

Scientist fights extremely aggressive and difficult-to-treat form of breast cancer

Biomedical scientist Kimberly L. Koss, PhD, is fighting an extremely aggressive and difficult-to-treat form of breast cancer.

17 Jul 2014

Lilly, Immunocore enter into co-discovery and co-development collaboration to develop cancer therapies

Eli Lilly and Company and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies.

16 Jul 2014

Engineering single-celled parasite in cat's intestine as cancer vaccine

Toxoplasma gondii (T. gondii) is a single-celled parasite that is happiest in a cat's intestines, but it can live in any warm blooded animal. Found worldwide, T. gondii affects about one-third of the world's population, 60 million of which are Americans.

16 Jul 2014

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs-an active immunotherapy and an oral medication-can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.

15 Jul 2014

Lung cancer and melanoma funders form first-ever research collaboration

LUNGevity Foundation today announced a partnership with the Lung Cancer Research Foundation and Melanoma Research Alliance to co-fund new innovative research on PD-1 inhibitor treatment options for both non-small cell lung cancer (NSCLC) and metastatic melanoma (MM) patients with brain metastases.

9 Jul 2014

New gene therapy may be effective for fighting fungal infections in cancer patients

Sleeping Beauty and fungal infections - not two items one would normally associate together, but for immunocompromised cancer patients they may prove to be a helpful combination.

9 Jul 2014

Novel cancer immunotherapy for dogs could benefit humans as well

As in humans, cancers in dogs have complex causes. The interaction of the environment, food, and genetic disposition are the most well known factors. Today nearly all methods of human medicine are basically available for dogs with cancer, but this was not true of cancer immunotherapy so far.

8 Jul 2014

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

A University of Pennsylvania-developed personalized immunotherapy has been awarded the U.S. Food and Drug Administration's Breakthrough Therapy designation for the treatment of relapsed and refractory adult and pediatric acute lymphoblastic leukemia (ALL).

7 Jul 2014

TxCell announces launch of POSITIVE project to automate manufacturing process for Ovasave

TxCell SA, a biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today the launch of, and funding awarded to, the POSITIVE project in collaboration with the Gene and Cell therapy Unit (UTCG) developing new antiviral cell-based immunotherapies and Biosafe, a Swiss private company, a developer of innovative solutions for cell processing.

4 Jul 2014

New collaborative fundraising effort focuses on AYA cancer

Leaders from Case Western Reserve University and University Hospitals this evening announced a new collaborative fundraising effort focused on Adolescent and Young Adult (AYA) cancer.

2 Jul 2014

New approach may help develop more effective immunotherapy for metastatic melanoma

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy.

1 Jul 2014

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.

30 Jun 2014

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma.

30 Jun 2014

Host-directed therapy: A new type of TB treatment

In a new study published in Nature, scientists describe a new type of tuberculosis (TB) treatment that involves manipulating the body's response to TB bacteria rather than targeting the bacteria themselves, a concept called host-directed therapy.

28 Jun 2014

Study shows caregivers' allergy perceptions are not always accurate

It's tough being the parent of a child with food allergies. Constant vigilance is needed for everything your child eats, when a single food item containing a hidden ingredient can be fatal.

28 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

New molecular analysis tool to detect targets for immunotherapy in early-stage breast cancers

Researchers find viable immunotherapy option for HIV-1 using fossil virus

First publication describing use of CytoSorb during cardiac surgery

Scientist fights extremely aggressive and difficult-to-treat form of breast cancer

Lilly, Immunocore enter into co-discovery and co-development collaboration to develop cancer therapies

Engineering single-celled parasite in cat's intestine as cancer vaccine

BAI and Novartis determine whether investigational drugs can prevent symptoms of Alzheimer's

Lung cancer and melanoma funders form first-ever research collaboration

New gene therapy may be effective for fighting fungal infections in cancer patients

Novel cancer immunotherapy for dogs could benefit humans as well

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Penn’s immunotherapy receives FDA's Breakthrough Therapy designation for ALL treatment

TxCell announces launch of POSITIVE project to automate manufacturing process for Ovasave

New collaborative fundraising effort focuses on AYA cancer

New approach may help develop more effective immunotherapy for metastatic melanoma

Cidara Therapeutics closes $32M Series A financing to advance novel echinocandin antifungal drug

EMA accepts for review Merck’s pembrolizumab MAA for treatment of advanced melanoma

Host-directed therapy: A new type of TB treatment

Study shows caregivers' allergy perceptions are not always accurate

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Immunotherapy News and Research

Latest Immunotherapy News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in